January 6, 2026

Alumis surges on late-stage trial win for lead drug in plaque psoriasis – Seeking Alpha

January 6, 2026

Alumis Stock Hits Record High on Psoriasis Drug Trial Results – Schaeffer’s Investment Research

January 6, 2026

Alumis’ TYK2 drug succeeds in key psoriasis studies, will seek FDA approval – Endpoints News

January 6, 2026

Deucravacitinib 6 mg Effective in Patients with Psoriasis Over 2 Years – HCPLive

January 6, 2026

Phase 3 Data Support Oral TYK2 Inhibitor Envudeucitinib for Psoriasis – Dermatology Times